DOCSLIB.ORG

BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from PipEracillin Tazobactam versus mERoPENem for treatment of bloodstream infections caused by cephalosporin-resistant Enterobacteriaceae - a non-inferiority randomized controlled trial (PeterPen) ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2020-040210 Article Type: Protocol Date Submitted by the 02-Jul-2020 Author: Complete List of Authors: Bitterman, Roni; Rambam Health Care Campus, Division of Infectious Diseases; Technion Israel Institute of Technology Ruth and Bruce Rappaport Faculty of Medicine Koppel, Fidi; Rambam Health Care Campus, Division of Infectious Diseases Mussini, Cristina; University Hospital Modena Geffen, Yuval; Rambam Health Care Campus, Microbiology Laboratory Chowers, Michal; Meir Medical Center, Infectious Diseases Unit; Tel Aviv University Sackler Faculty of Medicine Rahav, Galia; sheba medical center, Infectious Diseases Unit; Tel Aviv university, Sackler school of medicine Nesher, Lior; Soroka Medical Center, Infectious Diseases Unit; Ben- http://bmjopen.bmj.com/ Gurion University of the Negev Faculty of Health Sciences Ben-Ami, Ronen; Tel Aviv Sourasky Medical Center, Infectious Diseases Unit; Tel Aviv University Sackler Faculty of Medicine Turjeman, Adi; Rabin Medical Center, Internal Medicine E; Tel Aviv University Sackler Faculty of Medicine Huberman Samuel, Maayan ; Rabin Medical Center, Internal Medicine E Cheng, Matthew; McGill Interdisciplinary Initiative in Infection and Immunity Clinical Trials Platform Lee, Todd; McGill Interdisciplinary Initiative in Infection and Immunity on September 26, 2021 by guest. Protected copyright. Clinical Trials Platform Leibovici, Leonard; Rabin Medical Center, Internal Medicine E; Tel Aviv University Sackler Faculty of Medicine Yahav, Dafna; Rabin Medical Center, Infectious Diseases Unit; Tel Aviv University Sackler Faculty of Medicine Paul, Mical; Rambam Health Care Campus, Division of Infectious Diseases; Technion Israel Institute of Technology Ruth and Bruce Rappaport Faculty of Medicine Epidemiology < INFECTIOUS DISEASES, Infection control < INFECTIOUS Keywords: DISEASES, MICROBIOLOGY For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 38 BMJ Open BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 For peer review only 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 http://bmjopen.bmj.com/ 34 35 36 37 38 39 40 41 on September 26, 2021 by guest. Protected copyright. 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open Page 2 of 38 1 2 3 BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from 4 5 6 7 8 9 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined 10 in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors 11 who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance 12 with the terms applicable for US Federal Government officers or employees acting as part of their official 13 duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its 14 licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the 15 Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence. 16 17 The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to 18 the Submitting Author Forunless you peer are acting as review an employee on behalf only of your employer or a postgraduate 19 student of an affiliated institution which is paying any applicable article publishing charge (“APC”) for Open 20 Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and 21 intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative 22 Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set 23 out in our licence referred to above. 24 25 Other than as permitted in any relevant BMJ Author’s Self Archiving Policies, I confirm this Work has not been 26 accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate 27 material already published. I confirm all authors consent to publication of this Work and authorise the granting 28 of this licence. 29 30 31 32 33 34 35 36 37 http://bmjopen.bmj.com/ 38 39 40 41 42 43 44 45 on September 26, 2021 by guest. Protected copyright. 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 3 of 38 BMJ Open Page 1 1 2 3 PipEracillin Tazobactam versus mERoPENem for treatment of BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from 4 5 6 bloodstream infections caused by cephalosporin-resistant 7 8 9 Enterobacteriaceae - a non-inferiority randomized controlled trial 10 11 12 (PeterPen) 13 14 15 Roni Bitterman1,2, Fidi Koppel1, Cristina Mussini3, Yuval Geffen4, Michal 16 17 Chowers5,6, Galia Rahav6,7, Lior Nesher8,9, Ronen Ben-Ami6,10Adi Turjeman6,11, 18 For peer review only 19 Maayan Huberman Samuel11, Matthew P. Cheng12, Todd C. Lee12, Leonard 20 21 22 Leibovici6,11, Dafna Yahav6,13, Mical Paul1,2 for the PeterPen study group 23 24 25 26 27 28 1. Division of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel 29 30 31 2. The Ruth and Bruce Rappaport Faculty of Medicine, Technion- Israel Institute 32 33 of Technology, Haifa, Israel 34 35 3. Modena University Hospital, Modena, Italy 36 37 http://bmjopen.bmj.com/ 38 4. Microbiology Laboratory, Rambam Health Care Campus, Haifa, Israel 39 40 5. Infectious Diseases Unit, Meir Medical Center, Kefar Sava, Israel 41 42 6. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 43 44 45 7. Infectious Diseases Unit, The Chaim Sheba Medical Center at Tel Hashomer, on September 26, 2021 by guest. Protected copyright. 46 47 Ramat Gan, Israel 48 49 8. Infectious Diseases Unit, Soroka Medical Center, Be'er Sheva, Israel 50 51 9. Faculty of Health Sciences, Ben-Gurion University, Be'er Sheva, Israel 52 53 54 10. Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 55 56 11. Internal Medicine E, Rabin medical Center (Beilinson), Petah Tikva, Israel 57 58 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open Page 4 of 38 Page 2 1 2 3 12. McGill Interdisciplinary Initiative in Infection and Immunity Clinical Trials BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from 4 5 6 Platform, Montreal, Canada 7 8 13. Infectious Diseases Unit, Rabin medical Center (Beilinson), Petah Tikva, 9 10 Israel 11 12 13 14 15 16 17 Corresponding author: 18 For peer review only 19 20 Roni Bitterman, MD 21 22 23 Division of Infectious Diseases, 24 25 Rambam Health Care Campus, 26 27 Haifa 31096, Israel 28 29 30 Tel. +972-4-7772291 31 32 Fax: +972-4-7773284 33 34 Email: [email protected] 35 36 37 http://bmjopen.bmj.com/ 38 39 40 Word count: 3382 41 42 43 44 45 on September 26, 2021 by guest. Protected copyright. 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 5 of 38 BMJ Open Page 3 1 2 3 Key words: extended spectrum beta-lactamase, carbapenem, beta-lactam beta- BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from 4 5 6 lactamase inhibitor, randomized controlled trial 7 8 9 10 Strengths and limitations of the study 11 12 13 The question of whether combination beta-lactam beta-lactamase inhibitors 14 15 are non-inferior to carbapenems for the treatment of ESBL infections remains 16 17 unanswered. 18 For peer review only 19 20 We propose an open-label, randomized controlled trial comparing piperacillin- 21 22 tazobactam with meropenem for treatment of bloodstream infections with 23 24 cephalosporin-resistant Escherichia coli and Klebsiella.
Load more

Recommended publications
  • Scientific Program
    www.iscort.org.il Scientific Program 08.01.2019 - 12.01.2019, Eilat, Israel The Annual Meeting of The Israeli Society for Clinical Oncology and Radiation Therapy ISCORT wishes to express its gratitude to the following companies הוועדה המארגנת for their support of the 19th ISCORT Annual Meeting: Organizing Committee ISCORT 19 נשיא הכנס: :President פרופ׳ סלומון שטמר Platinum Sponsor Salomon M. Stemmer, MD Roche מזכירת הכנס: :Secretory ד״ר ולריה סמניסטי Gold Sponsor Valeria Semenysty, MD יו"ר הרדיותרפיה: :BMS Radiation Oncology Co-Chair פרופ׳ בן קורן MSD Ben W. Corn, MD הוועדה המדעית Silver Sponsor Scientific Committee ISCORT 19 Astellas יו"ר: פרופ׳ מיכל לוטם Astrazeneca Chairman: Michal Lotem, MD ד"ר אהרון אלון Boehringer Ingelheim Aaron Allen, MD ד"ר נועם אסנה Eli Lilly Noam Asna, MD ד"ר יאיר בר ISI Jair Bar, MD PhD ד"ר יהונתן כהן Novartis Yonathan Cohen, MD PhD פרופ׳ בן קורן Pfizer Ben W. Corn, MD ד"ר אלה עברון Rafa Ella Evron, MD ד"ר דניאלה כץ Daniela Katz, MD פרופ׳ גל מרקל Bronze Sponsor Gal Markel, MD PhD ד"ר אינה אוספובט AbbVie Inna Ospovat, MD ד"ר אביבית פאר Assuta Avivit Peer, MD ד"ר רות פרץ Bayer Ruth Perets, MD PhD Bolpharma ד"ר רפאל פפר Raphael Pfeffer, MD Dexcel Pharma ד"ר קרן רובינוב Keren Rouvinov, MD Isotopia ד"ר יקטרינה שולמן Katerina Shulman, MD Medison ד"ר אמיר זוננבליק Merck Amir Sonnenblick, MD ד"ר מרק ויגודה Nanostring Marc Wygoda, MD ד"ר אלונה זר Neopharm Alona Zer, MD ד"ר אביעד זיק Oncotest-Teva Aviad Zik, MD Perrigo החברה המארגנת Sanofi Organizing Company א.מ.
    [Show full text]
  • Dear Colleagues, It Is Our Pleasure to Invite You to the Annual Meeting Of
    Dear Colleagues, It is our pleasure to invite you to the Annual Meeting of the Israel Neurosurgical Society which will be held at the Galilion Hotel, Israel. Although the main focus of the meeting will be Brain Tumors, the organizers will be happy to consider interesting talks on related subjects. Confirmed speakers to date that will share their experiences and update us in the latest developments include: Prof. Volker A. Coenen Dept. of Stereotactic and Functional Neurosurgery, University of Freiberg; Neurosurgery Clinic, Freiberg, Germany Prof. Garth Rees Cosgrov Dept. of Neurological Surgery, Brigham and Women's Hospital, Boston, MA, USA Prof. Hans Henkes Neuroradiological Clinic, Katharinenhospital, Stuttgart, Germany Prof. Robert H. Rosenwasser Dept. of Neurological Surgery, Jefferson Hospital for Neuroscience, Philadelphia, PA, USA As in previous meetings, we hope that this event will provide the opportunity to reconnect and meet with colleagues and to strengthen professional and personal ties among our members. We hope that you will be able to join us. Sincerely, Prof. Yigal Shoshann Prof. Mony Benifla Dr. Racheli Grossman President Secretary Treasurer 1 TENTATIVE TIMETABLE Wednesday, May 13, 2020 Light Lunch Afternoon Sessions Dinner Evening Social Event Thursday, May 14, 2020 Morning Sessions Lunch Afternoon Sessions Dinner Evening Social Event Friday, May 15, 2020 Morning Sessions Afternoon Sessions End and Light Lunch Meeting Secretariat Target Conferences Ltd. PO Box 51227, Tel Aviv 6713818, Israel Tel: +972 3 5175150, Fax: +972 3 5175155 e-mail: [email protected] www.israelneurosurgery.com 2 SCIENTIFIC ADVISORY COMMITTEE ON FUNCTIONAL NEUROSURGERY AND EPILEPSY Zvi Israel - Lead Advisor Dept. of Neurosurgery, Hadassah Hebrew University Medical Center, Jerusalem Roberto Spiegelmann Dept.
    [Show full text]
  • The New Neonatal Care Center at Soroka Medical Center
    The New Neonatal Care Center at Soroka Medical Center 1 2 The New Neonatal Care Center at Soroka Medical Center The new Neonatal Care Center will serve all newborns in the Negev and provide full protection against missile attacks in accordance with the standards of the Home Front Command of the Israel Defense Forces. Soroka Medical Center: An Overview With 1,100 beds, Soroka Medical Center is among Israel’s largest and most advanced hospitals, and the country’s busiest. Soroka is the only major medical center in the entire Negev, serving a population of more than one million inhabitants, including 400,000 children, in a region that accounts for 60% of the country’s total land area. Soroka serves as the teaching hospital of both the Medical School of Ben-Gurion University, whose Faculty of Health Sciences is located on the hospital campus, and its Medical School for International Health. On par with leading international institutions, Soroka specializes in areas that include, for example, early detection and treatment of breast cancer using minimally invasive procedures; non-invasive removal of malignant tumors; trauma rehabilitation of children and adolescents; pediatric infectious diseases; and much more. Each year, excellent care is provided to more than 750,000 people at outpatient and clinic visits; 235,000 patients visit our Emergency Medicine Department (the busiest in the country); 80,000 inpatients fill our beds; over33 ,000 patients undergo surgery, and more than 17,000 babies are born. Soroka’s neonatal and pediatric departments provide family-centered intensive care with world-class survival rates. Soroka’s Trauma Unit is the largest and busiest in Israel, always on call, 24 hours a day, 365 days a year.
    [Show full text]
  • Spotted Fever Group Rickettsioses in Israel, 2010–2019
    Spotted Fever Group Rickettsioses in Israel, 2010–2019 Regev Cohen, Talya Finn, Frida Babushkin, Yael Paran, Ronen Ben Ami, Alaa Atamna, Sharon Reisfeld, Gabriel Weber, Neta Petersiel, Hiba Zayyad, Eyal Leshem, Miriam Weinberger, Yasmin Maor, Nicola Makhoul, Lior Nesher, Galia Zaide, Dar Klein, Adi Beth-Din, Yafi t Atiya-Nasagi ≈ In a multicenter, nationwide, retrospective study of pa- SFGRs are associated with 20 species of Rickettsia, tients hospitalized with spotted fever group rickettsiosis of which 16 are considered human pathogens (1,2). in Israel during 2010–2019, we identifi ed 42 cases, of Recent introduction of molecular methods provided which 36 were autochthonous. The most prevalent spe- more information about SFGR agents causing human cies was the Rickettsia conorii Israeli tick typhus strain (n disease and enabled their identifi cation, for which = 33, 79%); infection with this species necessitated inten- the clinical signifi cance of some remains lacking (3). sive care for 52% of patients and was associated with a R. conorii complex, the etiologic agent of Mediterra- 30% fatality rate. A history of tick bite was rare, found for nean spotted fever, includes 4 strains: R. conorii Mal- only 5% of patients; eschar was found in 12%; and leuko- ish (cause of Mediterranean spotted fever), R. conorii cytosis was more common than leukopenia. Most (72%) Astrakhan (cause of Astrakhan fever), R. conorii In- patients resided along the Mediterranean shoreline. For 3 dian tick typhus (cause of Indian tick typhus), and R. patients, a new Rickettsia variant was identifi ed and had been acquired in eastern, mountainous parts of Israel.
    [Show full text]
  • Scientific Program
    The 63th Annual Conference of the Israel Heart Society in association with the Israel Society of Cardiothoracic Surgery April 12-13 • 2016 • Tel Aviv, Israel SCIENTIFIC PROGRAM Paragon Israel (Dan Knassim) Paragon Tel/Fax:03-5767730/7 Israel (Dan Knassim) a Paragon Group Company [email protected] TUESDAY, APRIL 12, 2016 08:30-10:00 Interventional Cardiology I Hall A Chairs: Ariel Finkelstein, Ran Kornowski, Israel 08:30 Effect of Diameter of Drug-Eluting Stents Versus Bare-Metal Stents on Late Outcomes: a propensity score-matched analysis Amos Levi1,2, Tamir Bental1,2, Hana Veknin Assa1,2, Gabriel Greenberg1,2, Eli Lev1,2, Ran Kornowski1,2, Abid Assali1,2 1Cardiology, Rabin Medical Center, Israel 2Sackler Faculty of Medicine, Tel Aviv University, Israel 08:41 Percutaneous Valve-in-Valve Implantation for the Treatment of Aortic, Mitral and Tricuspid Structural Bioprosthetic Valve Degeneration Uri Landes1, Abid Assali1, Ram Sharoni1,2, Hanna Vaknin-Assa1, Katia Orvin1, Amos Levi1, Yaron Shapira1, Shmuel Schwartzenberg1, Ashraf Hamdan1, Tamir Bental1, Alexander Sagie1, Ran Kornowski1 1Department of Cardiology, Rabin Medical Center, Tel Aviv, Israel 2Department of Cardiac Surgery, Rabin Medical Center, Tel Aviv, Israel 08:52 Temporal Trends in Transcatheter Aortic Valve Implantation in Israel 2008-2014: Patient Characteristics, Procedural Issues and Clinical Outcome Uri Landes1, Alon Barsheshet1, Abid Assali1, Hanna Vaknin-Assa1, Israel Barbash3, Victor Guetta3, Amit Segev3, Ariel Finkelstein2, Amir Halkin2, Jeremy Ben-Shoshan2,
    [Show full text]
  • Therapeutic Hypothermia for Comatose Patients: VF Versus Other Initial Rhythm – Does It Matter?
    P13 - Posters - Intensive Cardiac Care Therapeutic Hypothermia for Comatose Patients: VF Versus Other Initial Rhythm – does it Matter? Avishag Laish-Farkash, Shlomi Matetzky, Samer Kassem, Alon Barsheshet, Hanny Haj-Iahia, Nataliya Ulanovsky, Hanoch Hod Heart Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 339 P13 - Posters - Intensive Cardiac Care The Value of Troponin-I Curve after Primary PCI for ST Elevation Myocardial Infarction Avishag Laish-Farkash 1,3, Hanoch Hod 1,3,Ben-Ami Sela2,3,Yoram Amsalem1,3, Athanasios Michailidis 1, Shlomi Matetzky 1,3 1 Heart Institute, 2 Institute for Chemical Pathology, Sheba Medical Center, Tel Hashomer, 3 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 340 P13 - Posters - Intensive Cardiac Care C-Reactive Protein as a Predictor of Active Coronary Disease and Worse Prognosis in Chest Pain Unit Dan Oieru 1,Roy Beigel1, Hanoch Hod 1,2, Pierre Chouraqui 1,2,Orly Goitein1, Eli Konen 1, Roy Beinart 1,Paul Fefer1,Ben-Ami Sela3,Ari Shamiss4,Jacob Or5, Shlomi Matetzky 1,2 1 Heart Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, 2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 3 Biochemical Laboratory, 4 Hospital Director, 5 Emergency Department, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 341 P13 - Posters - Intensive
    [Show full text]
  • Antibiotic Treatment for Invasive Listeriosis and Patient
    Antibiotic treatment for invasive listeriosis and patient outcome: a retrospective cohort study Yaakov Dickstein1, Yonatan Oster2, Orit Shimon3, Lior Nesher4, Dafna Yahav3,5, Yonit Wiener-Well6, Regev Cohen7,8, Ronen Ben-Ami3,9, Miriam Weinberger3,10, Galia Rahav3,11, Yasmin Maor3,12, Michal Chowers3,13, Ran Nir-Paz2, Mical Paul1,8 1 Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel 2 Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 3 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 4 Infectious Disease Institute, Soroka Medical Center, Ben-Gurion University of the Negev, Beer Sheba, Israel 5 Infectious Diseases Unit, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel 6 Infectious Disease Unit, Shaare Zedek Medical Center, Jerusalem, Israel 7 Infectious Diseases Unit, Sanz Medical Center–Laniado Hospital , Netanya, Israel 8 The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel 9 Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 10 Infectious Diseases Unit, Assaf Harofeh Medical Center, Zerifin, Israel 11 Infectious Disease Unit, Sheba Medical Center, Ramat Gan, Israel 12 Infectious Disease Unit, Wolfson Medical Center, Holon, Israel 13 Infectious Diseases Unit, Meir Medical Center, Kfar Saba, Israel Cumulative survival by treatment group Background: Current treatment started within 48 hours of culture recommendations for treatment of results and continued for a minimum duration invasive listeriosis suggest ampicillin- of 7 days. Patients who died within 48 hours of based therapy with the addition of an the index culture were excluded. The primary aminoglycoside. However, several outcome was 30-day all-cause mortality.
    [Show full text]
  • Mortality of Patients with Rheumatoid Arthritis Requiring Intensive Care: a Single-Center Retrospective Study
    Clinical Rheumatology (2019) 38:3015–3023 https://doi.org/10.1007/s10067-019-04651-w ORIGINAL ARTICLE Mortality of patients with rheumatoid arthritis requiring intensive care: a single-center retrospective study Yael Haviv-Yadid1 & Yulia Segal2 & Amir Dagan3,4,5 & Kassem Sharif6 & Nicola Luigi Bragazzi7 & Abdulla Watad6 & Howard Amital6,8,9 & Yehuda Shoenfeld8,9,10,11 & Ora Shovman6,8,9 Received: 20 February 2019 /Revised: 10 June 2019 /Accepted: 18 June 2019 /Published online: 26 June 2019 # International League of Associations for Rheumatology (ILAR) 2019 Abstract Background Patients with rheumatoid arthritis (RA) are at a high risk for life-threatening conditions requiring admission to the intensive care unit (ICU), but the data regarding the outcomes of these patients is limited. The present study investigated the clinical characteristics and outcomes of RA patients admitted to an ICU. Methods This retrospective cohort study included RA patients admitted to the general ICU of the Sheba Medical Center during 2002–2018. The main outcome was 30-day mortality. Using Student’s t test, χ2, and multivariable analyses, we compared the demographic, clinical, and laboratory parameters of the survivors and the non-survivors. Figures with p value < 0.05 were considered statistically significant. Results Forty-three RA patients were admitted to the ICU during the study period (mean age, 64.0 ± 13.1 years; 74.4% female). The leading causes of ICU admission were infection (72.1%), respiratory failure (72.1%), renal failure (60.5%), and septic shock (55.8%). The 30-day mortality rate was 34.9%, with infection (9/15, 60%) as the most frequent cause.
    [Show full text]
  • The Peres Center for Peace, Tel-Aviv April 12Th, 2019
    April 12th, 2019 The Peres Center for Peace, Tel-Aviv BREAST CANCER INNOVATIONS The Israeli Society for Clinical Oncology and Radiation Therapy and Roche are Pleased to Invite You to an Enriching and Educating Meeting with our Distinguished Guest Speaker: Prof. Charles E. Geyer Please Send the Attached Registration Form to A.M Knasim No Later than April 1st 2019 E-mail: [email protected] Tel: 03-6081520 Fax: 03-6081522 Prof. Charles E. Geyer Friday, 12th April 2019 • Professor of Medicine 08:00-09:00 Welcome Reception • Harrigan, Haw, Luck Families Chair in Cancer Research 09:00-09:10 Opening Remarks • Virginia Commonwealth University, Massey Dr. Noa Efrat Ben-Baruch Cancer Center Head, Israeli Breast Cancer Group • Associate Director of Clinical Research Head, Department of Oncology Kaplan Medical Center Charles E. Geyer, Jr. is Professor of Medicine and the Harrigan, Haw, Luck Families Chair in Cancer Research at Virginia Commonwealth University Massey Chairmen: Dr. Georgeta Fried Cancer Center, an NCI-designated Cancer Center. He serves as Associate Director Head Breast Cancer Unit of Clinical Research for the Massey Cancer Center with oversight responsibility Rambam Medical Center for all cancer-related clinical research activities within the Center. Prof. Geyer Dr. Margarita Tokar has devoted most of his academic career on the design and conduct of multi- institutional, phase III clinical trials in breast cancer with a particular focus on Senior Oncologist the development of HER2 targeted therapies. He has served in several leadership Soroka University Medical Center positions for multi-institution research initiatives. These include vice-chair of the 09:10-09:30 Personalized Nanothechnologies in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Committee Management of Breast Cancer from 1999 until 2007, Associate Director of Medical Affairs from 2002 to 2006 and Director of Medical Affairs for NSABP from 2006 to 2011.
    [Show full text]
  • APF Newsletter, Winter 2006 – 2007
    Winter 2006-2007 APF A Newsletter of the From The President AmericanEmergency Physicians andFellowship Disaster Preparednessfor Medicine in Israel Course News in Israel From The President Israel in Crisis Mission August 2006 would like to share with our members and donors the important by Dr. Dan Moskowitz I APF activities of the past 6 months. his past August, I had the privilege of being invited to par- 1. APF ISRAEL CRISIS FUND REPORT After placing on our T ticipate in an Emergency APF Mission to Israel with APF website and sending a special crisis appeal from Dr. Danny Laor, Board members Drs. Mike Frogel, Paul Liebman and Charles the Deputy Minister for Emergency Preparedness, on the critical Kurtzer. Dr. Boaz Tadmor organized an incredible, whirlwind needs of the Northern hospitals, it was very gratifying indeed that over $100,000 tour for us, only two days after the cessation of hostilities in was received for our Crisis Fund. All of this will be distributed to hospitals such as Israel. We were provided with a unique glimpse of the Israeli Sieff Hospital in Safed, Poriya in Tiberias, Western Galilee Medical Center in Nahariya, and Rambam Medical Center in Haifa, with the hospital CEO’s given the healthcare system under stress, including face-to-face meet- discretion as to how best to utilize these funds to help their hospital in light of the ings with top healthcare officials, as well as visits to the trau- recent crisis. matized hospitals in northern Israel. Perhaps most importantly, we visited 2. MISSION TO ISRAEL Three APF Board members, Drs.
    [Show full text]
  • Antibiotic Treatment for Invasive Nonpregnancy-Associated Listeriosis and Mortality: a Retrospective Cohort Study
    European Journal of Clinical Microbiology & Infectious Diseases (2019) 38:2243–2251 https://doi.org/10.1007/s10096-019-03666-0 ORIGINAL ARTICLE Antibiotic treatment for invasive nonpregnancy-associated listeriosis and mortality: a retrospective cohort study Yaakov Dickstein1 & Yonatan Oster2 & Orit Shimon3 & Lior Nesher4 & Dafna Yahav3,5 & Yonit Wiener-Well6 & Regev Cohen7,8 & Ronen Ben-Ami3,9 & Miriam Weinberger3,10 & Galia Rahav3,11 & Yasmin Maor3,12 & Michal Chowers3,13 & Ran Nir-Paz2 & Mical Paul1,8 Received: 22 May 2019 /Accepted: 30 July 2019 /Published online: 10 August 2019 # Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Little evidence exists addressing the clinical value of adding gentamicin to ampicillin for invasive listeriosis. A multicenter retrospective observational study of nonpregnant adult patients with invasive listeriosis (primary bacteremia, central nervous system (CNS) disease, and others) in 11 hospitals in Israel between the years 2008 and 2014 was conducted. We evaluated the effect of penicillin-based monotherapy compared with early combination therapy with gentamicin, defined as treatment started within 48 h of culture results and continued for a minimum of 7 days. Patients who died within 48 h of the index culture were excluded. The primary outcome was 30-day all-cause mortality. A total of 190 patients with invasive listeriosis were included. Fifty-nine (30.6%) patients were treated with early combination therapy, 90 (46.6%) received monotherapy, and 44 (22.8%) received other treatments. Overall 30-day mortality was 20.5% (39/190). Factors associated with mortality included lower baseline functional status, congestive heart failure, and higher sequential organ failure assessment score.
    [Show full text]
  • Comprehensive Cancer Center This Is Untenable
    CompSorrehensokaive Cancer Center SOROKA MEDICAL CENTER Today’s Challenge Today’s FACTS Tel Aviv 60 Percent of Israel’s landmass 1,000,000 Total Population Jerusalem 300 Percent increase of cancer cases in the Negev over past 20 years due in large part to increase in population Last year at Soroka Medical Center: Gaza Soroka Hospitalizations in the Oncology and Medical 1,645 Hematology Wards Center Beer Patients cared for in the Ambulatory Sheva 15,923 Oncology and Hematology Units 24,451 Patients cared for in the Oncology and The Negev Hematology Clinics 17,987 Radiation therapy treatments 40,243 Chemotherapy treatments 100,249 Total number of cancer-related hospital visits miles a person in the southern tip of the Negev must 221 currently travel to reach a comprehensive cancer center This is untenable. 3 There is NO comprehensive cancer center in the Negev. Coping with cancer is difficult enough under the best of circumstances. There are the elements of fear and doubt, questions about how to handle it with the family and how to get the most effective treatment. The challenge is greatly compounded when the closest comprehensive cancer center is hours away and transportation is limited. Many residents in the Negev are impoverished and from traditional societies. If care is not easily accessible they simply will not get treatment. Chemotherapy treatment today 4 Growing Needs and Changing Winds Components for cancer treatment that do exist arose out of the Negev’s growing need for cancer care and they are scattered and overcrowded. Even more pressing is the fact that the Oncology Department is housed in Soroka Medical Center’s emergency underground hospital.
    [Show full text]